Loading…
← CockpitCompetitor Analysis › MBX MBX Biosciences, Inc.Open in the cockpit ↗

MBX Biosciences, Inc.MBXCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.

Momentum leader 84
Mkt cap
$2.65B
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$28.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.6%
Hurdle
n/a
no reverse DCF
Next earnings
124 days
22 Mar 2027
Close · USD$53.42
1D+0.6%
1W-7.5%
1M-0.1%
3M-19.5%
6M+70.0%
YTD+69.4%
1Y+108.6%
ATR %7.0%
Beta1.31
52w lowhigh26.5% off high

What MBX Biosciences does

Develops long-acting peptide therapies for endocrine and metabolic diseases including hypoparathyroidism and obesity.

Has no product to sell, so it is funded by money raised from investors, and any future income would come from selling its own drugs or licensing them to a larger drugmaker. Its platform engineers peptides to be dosed less often, such as once weekly. It listed in 2024.

Products and services

  • MBX 2109 (hypoparathyroidism)
  • MBX 1416 (obesity, GLP-1/GIP)

Customers

  • Endocrinologists (post-approval)

Where it sits in the supply chain

  • Health Care
  • Biotechnology
  • Peptide therapeutics for endocrine…

What could go right

  • Hypoparathyroidism pivotal data
  • Entry into the large obesity/metabolic market

What could go wrong

  • Clinical trial failure risk
  • Crowded GLP-1/obesity competitive field

Moat: none (IP / patents). Clinical-stage biotech with proprietary long-acting peptide chemistry but no approved products yet.

Headquarters: Carmel, Indiana, US · Founded: 2019 · Employees: 63

Named competitors

MBX Biosciences at a glance

Size MBX Biosciences (MBX) is a United States Health Care company (Biotechnology) with a market value of $2.65B, the 1615th largest of 3,085 United States companies the cockpit tracks. Shares closed at $53.42 on 18 Nov 2026.

Performance Over six months the shares gained 70.0%, against -2.0% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Short interest Short interest is 8.9% of the free float (30 Oct 2026).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10015020021 May 202621 Aug 202618 Nov 2026MBX 168Peer median 98
Six months, rebased to 100: MBX Biosciences against the median of its 20 peers (local-currency closes).

MBX Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$343,000-$248,000-$244,000-$157,000-$56,000
EBITDA-$160M-$97.8M-$68.0M-$35.2M-$25.1M
Net income-$145M-$87.0M-$61.9M-$32.6M-$26.1M
Free cash flow-$99.3M-$81.9M-$55.6M-$32.1M-$23.6M
Capital expenditure$3.32M$1.93M$874,000$129,000$441,000
Total debt$3.29M$598,000$213,000$518,000$527,000

Quarterly statements and history in the cockpit →

MBX Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%-25%0%+25%0283006887XNCR6882789688BAVA3001422228RUBICONDNLITLXADMA300255RCUSXERSLKFTVIMIAN302440MBX6-month return →1-month return →
Up and to the right = strong over both horizons. MBX Biosciences is the large dot.

MBX Biosciences competitors and peer comparison

Head to head with its named competitors (MBX vs ASND vs NOVO-B.CO vs LLY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
MBX Biosciences MBX$2.65B+70%n/an/an/an/a
Ascendis Pharma A/S ASND$16.9B+12%+94%18%11.7×19.2%
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%3.9×-0.5%
Lilly (Eli) LLY$1.30T+36%+46%51%15.6×6.5%

How MBX Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

MBX Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureMBXPeer medianRank in peer set
1-month return-0.1%-2.6%10th highest of 21
6-month return+70.0%-2.0%3rd highest of 21
Distance from 52-week high-26.5%-30.1%8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
MBX Biosciences MBXUnited States$2.65B+70%n/an/an/an/an/a
HLB 028300.KSSouth Korea$2.69B-49%+26%-96%38.7×n/an/a
Sunshine Lake Pharma 6887.HKHong Kong$2.72B-7%+20%-3%5.9×n/an/a
Xencor XNCRUnited States$2.58B+204%+34%-73%11.7×n/an/a
Xiamen Amoytop Biotech 688278.SSChina$2.56B-27%+18%27%4.3×-0.6%+36.0%
Zai Lab 9688.HKHong Kong$2.79B+23%0%-63%5.4×n/an/a
Bavarian Nordic A/S BAVA.CODenmark$2.82B+23%-8%18%2.6×-4.3%+27.4%
Walvax Biotechnology 300142.SZChina$2.48B-26%-23%5%9.4×29.5%-3.8%
XtalPi 2228.HKHong Kong$2.87B-34%+4%-127%21.3×n/an/a
Rubicon Research RUBICON.NSIndia$2.94B+68%+37%21%13.2×n/an/a
Denali Therapeutics DNLIUnited States$2.95B-2%n/a-2,488%115.4×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%3.8×n/an/a
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%6.0×-0.8%+64.6%
Hebei Changshan Biochemical Pharmaceutical 300255.SZChina$2.33B-59%0%-25%19.4×n/an/a
Arcus Biosciences RCUSUnited States$2.27B-34%-58%-475%17.6×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%8.7×29.5%+70.2%
Lakefront Biotherapeutics LKFT.ASNetherlands$2.26B+31%+223%64%n/an/an/a
Vimian VIMIAN.STSweden$2.26B+51%+8%19%5.0×13.4%+44.5%
SKBS 302440.KSSouth Korea$2.25B-12%+11%-23%4.3×n/an/a
Pharvaris PHVSUnited States$2.21B+7%n/an/an/an/an/a

Questions

Who are MBX Biosciences's main competitors?
Named competitors: Ascendis Pharma (ASND), Novo Nordisk (NOVO-B.CO), Eli Lilly (LLY). The cockpit's measured peer set (industry) also includes HLB (028300.KS), Sunshine Lake Pharma (6887.HK), Xencor (XNCR), Xiamen Amoytop Biotech (688278.SS), Zai Lab (9688.HK), Bavarian Nordic A/S (BAVA.CO).
How has MBX Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +70.0% against -2.0% for the median peer; over one year +108.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.